cis-Dichlorodiammineplatinum (II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung

J. C. Britell, R. T. Eagan, J. N. Ingle, E. T. Creagen, J. Rubin, S. Frytak

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Forty-one patients with proven metastatic adenocarcinoma of the lung were randomized into two comparable groups after stratification for performance status and presence of measurable or evaluable disease. Treatment 1 consisted of cis-dichlorodiammineplatinum(II) (P) at a dose of 15 mg/m 2/day by iv push on Days 1-5 every 4 weeks. Upon progression or the onset of renal toxic effects, patients were crossed over to cyclophosphamide (C) at a dose of 400 mg/m 2, and adriamycin (A) at a dose of 40 mg/m 2, both given by iv push on Day 1 every 4 weeks. Treatment 2 (CAP-I) consisted of C-A in the same doses as above plus concurrent P, 40 mg/m 2 by iv push on Day 1 every 4 weeks. Eight patients receiving P developed serum creatinine values ≥1.5 mg/100 ml versus one patient receiving CAP-I (P = 0.05). Objective regressions occurred in two of 22 patients with P, five of 17 with C-A, and eight of 19 with CAP-I (P = 0.025; CAP-I versus P). There was a significant increase in the median duration of regression in patients responding to C-A following P (267 days) versus patients responding to CAP-I (95 days). The improved rate of response with CAP-I and the prolonged duration of response with C-A following P suggest a potentiating effect between P and C-A whether given simultaneously or sequentially.

Original languageEnglish (US)
Pages (from-to)1207-1210
Number of pages4
JournalCancer Treatment Reports
Volume62
Issue number8
StatePublished - 1978

Fingerprint

Doxorubicin
Cyclophosphamide
Cisplatin
Poisons
Adenocarcinoma of lung
Creatinine
Kidney
Therapeutics
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

cis-Dichlorodiammineplatinum (II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. / Britell, J. C.; Eagan, R. T.; Ingle, J. N.; Creagen, E. T.; Rubin, J.; Frytak, S.

In: Cancer Treatment Reports, Vol. 62, No. 8, 1978, p. 1207-1210.

Research output: Contribution to journalArticle

@article{4267cddb8d204ceda263b90ba0dcba0c,
title = "cis-Dichlorodiammineplatinum (II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung",
abstract = "Forty-one patients with proven metastatic adenocarcinoma of the lung were randomized into two comparable groups after stratification for performance status and presence of measurable or evaluable disease. Treatment 1 consisted of cis-dichlorodiammineplatinum(II) (P) at a dose of 15 mg/m 2/day by iv push on Days 1-5 every 4 weeks. Upon progression or the onset of renal toxic effects, patients were crossed over to cyclophosphamide (C) at a dose of 400 mg/m 2, and adriamycin (A) at a dose of 40 mg/m 2, both given by iv push on Day 1 every 4 weeks. Treatment 2 (CAP-I) consisted of C-A in the same doses as above plus concurrent P, 40 mg/m 2 by iv push on Day 1 every 4 weeks. Eight patients receiving P developed serum creatinine values ≥1.5 mg/100 ml versus one patient receiving CAP-I (P = 0.05). Objective regressions occurred in two of 22 patients with P, five of 17 with C-A, and eight of 19 with CAP-I (P = 0.025; CAP-I versus P). There was a significant increase in the median duration of regression in patients responding to C-A following P (267 days) versus patients responding to CAP-I (95 days). The improved rate of response with CAP-I and the prolonged duration of response with C-A following P suggest a potentiating effect between P and C-A whether given simultaneously or sequentially.",
author = "Britell, {J. C.} and Eagan, {R. T.} and Ingle, {J. N.} and Creagen, {E. T.} and J. Rubin and S. Frytak",
year = "1978",
language = "English (US)",
volume = "62",
pages = "1207--1210",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - cis-Dichlorodiammineplatinum (II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung

AU - Britell, J. C.

AU - Eagan, R. T.

AU - Ingle, J. N.

AU - Creagen, E. T.

AU - Rubin, J.

AU - Frytak, S.

PY - 1978

Y1 - 1978

N2 - Forty-one patients with proven metastatic adenocarcinoma of the lung were randomized into two comparable groups after stratification for performance status and presence of measurable or evaluable disease. Treatment 1 consisted of cis-dichlorodiammineplatinum(II) (P) at a dose of 15 mg/m 2/day by iv push on Days 1-5 every 4 weeks. Upon progression or the onset of renal toxic effects, patients were crossed over to cyclophosphamide (C) at a dose of 400 mg/m 2, and adriamycin (A) at a dose of 40 mg/m 2, both given by iv push on Day 1 every 4 weeks. Treatment 2 (CAP-I) consisted of C-A in the same doses as above plus concurrent P, 40 mg/m 2 by iv push on Day 1 every 4 weeks. Eight patients receiving P developed serum creatinine values ≥1.5 mg/100 ml versus one patient receiving CAP-I (P = 0.05). Objective regressions occurred in two of 22 patients with P, five of 17 with C-A, and eight of 19 with CAP-I (P = 0.025; CAP-I versus P). There was a significant increase in the median duration of regression in patients responding to C-A following P (267 days) versus patients responding to CAP-I (95 days). The improved rate of response with CAP-I and the prolonged duration of response with C-A following P suggest a potentiating effect between P and C-A whether given simultaneously or sequentially.

AB - Forty-one patients with proven metastatic adenocarcinoma of the lung were randomized into two comparable groups after stratification for performance status and presence of measurable or evaluable disease. Treatment 1 consisted of cis-dichlorodiammineplatinum(II) (P) at a dose of 15 mg/m 2/day by iv push on Days 1-5 every 4 weeks. Upon progression or the onset of renal toxic effects, patients were crossed over to cyclophosphamide (C) at a dose of 400 mg/m 2, and adriamycin (A) at a dose of 40 mg/m 2, both given by iv push on Day 1 every 4 weeks. Treatment 2 (CAP-I) consisted of C-A in the same doses as above plus concurrent P, 40 mg/m 2 by iv push on Day 1 every 4 weeks. Eight patients receiving P developed serum creatinine values ≥1.5 mg/100 ml versus one patient receiving CAP-I (P = 0.05). Objective regressions occurred in two of 22 patients with P, five of 17 with C-A, and eight of 19 with CAP-I (P = 0.025; CAP-I versus P). There was a significant increase in the median duration of regression in patients responding to C-A following P (267 days) versus patients responding to CAP-I (95 days). The improved rate of response with CAP-I and the prolonged duration of response with C-A following P suggest a potentiating effect between P and C-A whether given simultaneously or sequentially.

UR - http://www.scopus.com/inward/record.url?scp=0018123431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018123431&partnerID=8YFLogxK

M3 - Article

C2 - 688256

AN - SCOPUS:0018123431

VL - 62

SP - 1207

EP - 1210

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 8

ER -